Advertisement
Screener

Organon & Co. (OGN) Return on Tangible Equity

2.8 / 5 stars · 68/120 Roast Me

Organon & Co. Return Tang Equity

Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • Organon & Co. return tang equity for the quarter ending 2026-06-30 was -4.91%, a change of 8.28% year-over-year.
  • Organon & Co. return tang equity for the quarter ending 2026-03-31 was -5.66%, a change of 7.84% year-over-year.
  • Organon & Co. return tang equity for the quarter ending 2025-12-31 was -4.13%, a change of 11.24% year-over-year.
  • Organon & Co. return tang equity for the quarter ending 2025-09-30 was -9.80%, a change of 16.90% year-over-year.
  • Organon & Co. return tang equity for fiscal 2025 was -4.13%, a change of 11.24% from fiscal 2024.
  • Organon & Co. return tang equity for fiscal 2024 was -15.37%, a change of 4.28% from fiscal 2023.
  • Organon & Co. return tang equity for fiscal 2023 was -19.65%, a change of -4.73% from fiscal 2022.
  • Organon & Co. return tang equity for fiscal 2022 was -14.93%, a change of 5.05% from fiscal 2021.
Available history
2019-12-31 to 2026-06-30
Data captured

Historical Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2026-06-30-4.91%$209M-$4.26B
2026-03-31-5.66%$246M-$4.35B
2025-12-31-4.13%$187M-$4.53B
2025-09-30-9.80%$501M-$5.11B
2025-06-30-13.19%$700M-$5.31B
2025-03-31-13.50%$750M-$5.56B
2024-12-31-15.37%$864M-$5.62B
2024-09-30-26.70%$1.3B-$4.87B
2024-06-30-19.44%$1B-$5.14B
2024-03-31-19.86%$1.05B-$5.27B
2023-12-31-19.65%$1.02B-$5.21B
2023-09-30-10.17%$585M-$5.75B
2023-06-30-13.11%$754M-$5.75B
2023-03-31-12.51%$746M-$5.96B
2022-12-31-14.93%$917M-$6.14B
2022-09-30-15.95%$1.01B-$6.34B
2022-06-30-17.36%$1.11B-$6.38B
2022-03-31-19.94%$1.3B-$6.52B
2021-12-31-19.98%$1.35B-$6.76B
2021-09-30-21.97%$1.52B-$6.9B
2021-06-30-24.02%$1.74B-$7.25B
2021-03-31-511.29%$1.86B-$363M
2020-12-31568.42%$2.16B$380M

Annual Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2025-12-31-4.13%$187M-$4.53B
2024-12-31-15.37%$864M-$5.62B
2023-12-31-19.65%$1.02B-$5.21B
2022-12-31-14.93%$917M-$6.14B
2021-12-31-19.98%$1.35B-$6.76B
2020-12-31568.42%$2.16B$380M
2019-12-3145.74%$3.22B$7.04B

Similar stocks

Stock NameCountryMarket CapPE Ratio
IDEAYA Biosciences, Inc. (IDYA)United States$3.540B-20.52
Xenon Pharmaceuticals Inc. (XENE)$3.684B-14.27
ACADIA PHARMACEUTICALS INC (ACAD)United States$3.823B11.45
Amylyx Pharmaceuticals, Inc. (AMLX)United States$3.361B-13.15
AbCellera Biologics Inc. (ABCL)$3.879B-14.59
Enliven Therapeutics, Inc. (ELVN)United States$3.307B-35.07
Arcutis Biotherapeutics, Inc. (ARQT)United States$3.303B115.47
Arcus Biosciences, Inc. (RCUS)United States$3.188B-8.52
Dyne Therapeutics, Inc. (DYN)United States$3.084B-7.09
Tango Therapeutics, Inc. (TNGX)United States$4.154B-42.53